Literature DB >> 21394568

The management of hypertensive emergencies in children after stem cell transplantation.

D G Horn1, M N Trame, G Hempel.   

Abstract

AIM OF THE REVIEW: This work presents a short overview on the available data about drugs that are currently used to treat hypertensive emergencies in children with a focus on incidents after stem cell transplantation. It shows that the pediatric use of all hypotensive agents appears to be mainly based on personal experience of the attending physicians rather than on convincing clinical trials.
METHOD: A literature search was performed in MEDLINE, through PubMed, using the medical subject headings (MeSH) hypertensive emergencies, nifedipine, nicardipine, and children. Further articles were identified by checking cross-references of articles and books.
RESULTS: Hypertensive emergencies in children after stem cell transplantation usually have a renal etiology, because of the treatment with the calcineurin inhibitors cyclosporine and tacrolimus. In these severe cases an immediate action is necessary to avoid possible appearance or exacerbation of endorgan damage. Because of their mechanism of action and a potential nephroprotective effect calcium channel blockers may be particularly suitable in cases of hypertensive emergencies. An intravenous application of nifedipine may compensate the difficulties of accurate dosing, but keeping in mind possible severe side effects and the lack of published experience its use in children is at least questionable. Nicardipine appears to be the hypotensive agent of first choice. In adults, the treatment of hypertensive emergencies with intravenous nicardipine is well-documented, but for an evaluation of safety in pediatric use, the published studies and case reports appear to be barely adequate.
CONCLUSION: The actual treatment approaches vary widely, demonstrating the lack of hard science on which current treatment of hypertensive emergencies in children is based. The hypotensive agent for the individual situation should be chosen considering the properties, side effects, the limited experiences with its use and the patient's anamnesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21394568     DOI: 10.1007/s11096-011-9495-0

Source DB:  PubMed          Journal:  Int J Clin Pharm


  119 in total

1.  Cellular mechanisms of vascular injury mediated by calcineurin inhibitors.

Authors:  Santiago Lamas
Journal:  Kidney Int       Date:  2005-08       Impact factor: 10.612

Review 2.  Beta-blockers for cardiac CT: a primer for the radiologist.

Authors:  Harpreet K Pannu; William Alvarez; Elliot K Fishman
Journal:  AJR Am J Roentgenol       Date:  2006-06       Impact factor: 3.959

3.  Hydralazine-induced lupus.

Authors:  Sonal Singh
Journal:  South Med J       Date:  2006-01       Impact factor: 0.954

4.  Acute renal failure after overdose of labetalol.

Authors:  A J Smit; P O Mulder; P E de Jong; G K van der Hem
Journal:  Br Med J (Clin Res Ed)       Date:  1986-11-01

5.  Nicardipine to control mean arterial pressure after cardiothoracic surgery in infants and children.

Authors:  J D Tobias
Journal:  Am J Ther       Date:  2001 Jan-Feb       Impact factor: 2.688

6.  Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81.

Authors:  J George Zhang; Shangara S Dehal; Thuy Ho; Jennifer Johnson; Catherine Chandler; Andrew P Blanchard; Robert J Clark; Charles L Crespi; David M Stresser; James Wong
Journal:  Drug Metab Dispos       Date:  2006-02-24       Impact factor: 3.922

Review 7.  Advances in the pathogenesis and management of hypertensive crisis.

Authors:  Hiren P Patel; Mark Mitsnefes
Journal:  Curr Opin Pediatr       Date:  2005-04       Impact factor: 2.856

8.  Hypertension in childhood cancer: a frequent complication of certain tumor sites.

Authors:  Chrystele Madre; Daniel Orbach; Veronique Baudouin; Herve Brisse; Farida Bessa; Gudrun Schleiermacher; Helene Pacquement; Francois Doz; Jean Michon
Journal:  J Pediatr Hematol Oncol       Date:  2006-10       Impact factor: 1.289

9.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

Review 10.  [Treatment of peri- and postoperative hypertensive emergencies].

Authors:  A Link; S Selejan; K Walenta; J C Reil; M Böhm
Journal:  Dtsch Med Wochenschr       Date:  2009-03-24       Impact factor: 0.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.